{"filing":{"accession_number":"0001104659-26-104929","cik":"0001819576","ticker":"LQDA","company_name":"Liquidia Corp","form":"8-K","filing_date":"2026-09-03","report_date":"2026-09-03","primary_document":"tm2624724d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1819576/000110465926104929/tm2624724d1_8k.htm"},"events":[{"id":31480,"run_id":28887,"accession_number":"0001104659-26-104929","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Liquidia announced FDA Fast Track designation for YUTREPIA (treprostinil) inhalation powder for treatment of Raynaud's phenomenon associated with systemic sclerosis. This is a regulatory milestone that accelerates development and review timelines for a clinical-stage indication, representing material progress in the company's pipeline. While not a completed M\u0026A transaction or earnings release, this operational/regulatory achievement would affect a reasonable investor's assessment of the company's development prospects and competitive position.","company_name":"Liquidia Corp","ticker":"LQDA","filing_date":"2026-09-03","form":"8-K","submitted_at":null,"items":[{"id":34375,"accession_number":"0001104659-26-104929","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Liquidia announced FDA Fast Track designation for YUTREPIA (treprostinil) inhalation powder for treatment of Raynaud's phenomenon associated with systemic sclerosis. This is a regulatory milestone that accelerates development and review timelines for a clinical-stage indication, representing material progress in the company's pipeline. While not a completed M\u0026A transaction or earnings release, this operational/regulatory achievement would affect a reasonable investor's assessment of the company's development prospects and competitive position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-03T12:02:14.254897+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34375,"accession_number":"0001104659-26-104929","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Liquidia announced FDA Fast Track designation for YUTREPIA (treprostinil) inhalation powder for treatment of Raynaud's phenomenon associated with systemic sclerosis. This is a regulatory milestone that accelerates development and review timelines for a clinical-stage indication, representing material progress in the company's pipeline. While not a completed M\u0026A transaction or earnings release, this operational/regulatory achievement would affect a reasonable investor's assessment of the company's development prospects and competitive position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-03T12:02:14.254897+00:00","company_name":"Liquidia Corp","ticker":"LQDA","filing_date":"2026-09-03"}]}